Transgene is designing and developing next-generation immunotherapeutics against cancer
TG4050
One patient, one cancer, one vaccine
TG4050 is an individualized neoantigen cancer vaccines from Transgene’s myvac® platform, based on multiple advanced genetic engineering technologies and cutting-edge artificial intelligence capabilities. TG4050 is being evaluated in a Phase I/II clinical trial.
TG4050 video
Watch Alessandro Riva presenting first clinical benefits of neoantigen cancer vaccine, TG4050, in head & neck cancer at AACR 2024
Innovative technologies
Push the boundaries of immunotherapy
Transgene combines cutting-edge technologies, a multidisciplinary team and a prestigious international network.
Discover our myvac® platform
Discover our invir.IO® platform
Oncolytic viruses
A new generation of products
These innovative multifunctional OVs, from Transgene’s invir.IO® platform, are able to modulate the tumor microenvironment to better attack cancer.
Oncolytic viruses video
Three therapeutic approaches
Transgene’s immunotherapies harness the mechanisms of the immune response to enable the patient’s body to fight against disease.
- ESMO
ESMO 2024
Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatments
Donwload Press release (PDF)
Donwload the Poster (PDF) - Presentation
Transgene in a nutshell
Corporate Presentation
Universal Registration Document
Press releases
- October 14, 2024 - Transgene Provides Update on Phase II Trial of Therapeutic Cancer Vaccine TG4001 in Recurrent or Metastatic HPV16-Positive Cervical and Anogenital Cancers
- October 7, 2024 - Transgene to Present a Poster on Updated Data for TG4050 at SITC 2024
- September 24, 2024 - Transgene to Report Major Clinical Data before the end of 2024 – Confirmed Financial Visibility until Q4 2025
Last publications
- October 7, 2024 - Transgene to Present a Poster on Updated Data for TG4050 at SITC 2024
- September 14, 2024 - Initial clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb, administered as single agent and in combination with pembrolizumab in patients with advanced solid tumors
- September 10, 2024 - TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvionment
